Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E42.38 EPS (ttm)1.56 Insider Own0.04% Shs Outstand2.75B Perf Week5.07%
Market Cap181.61B Forward P/E15.84 EPS next Y4.18 Insider Trans-16.71% Shs Float2.73B Perf Month1.89%
Income4.35B PEG7.05 EPS next Q0.87 Inst Own75.70% Short Float0.77% Perf Quarter4.72%
Sales39.93B P/S4.55 EPS this Y-10.00% Inst Trans0.30% Short Ratio2.37 Perf Half Y11.32%
Book/sh14.51 P/B4.56 EPS next Y8.69% ROA4.50% Target Price- Perf Year14.70%
Cash/sh5.56 P/C11.91 EPS next 5Y6.02% ROE10.40% 52W Range55.10 - 66.80 Perf YTD12.38%
Dividend1.88 P/FCF107.40 EPS past 5Y-7.00% ROI6.20% 52W High-0.96% Beta0.82
Dividend %2.84% Quick Ratio1.30 Sales past 5Y-3.70% Gross Margin75.90% 52W Low20.07% ATR0.83
Employees68000 Current Ratio1.60 Sales Q/Q1.30% Oper. Margin14.40% RSI (14)65.36 Volatility1.48% 1.16%
OptionableYes Debt/Eq0.71 EPS Q/Q39.30% Profit Margin10.90% Rel Volume1.51 Prev Close66.02
ShortableYes LT Debt/Eq0.59 EarningsAug 01 BMO Payout117.50% Avg Volume8.95M Price66.16
Recom- SMA202.66% SMA503.84% SMA2005.37% Volume13,504,412 Change0.21%
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jun-25-17 07:41AM  The FDA Has Never Approved a Drug Like This in Its 111-Year History Motley Fool
Jun-24-17 05:00PM  Could Merck and Leap Union Be the One for Keytruda? TheStreet.com
Jun-23-17 09:00PM  On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog TheStreet.com
Jun-22-17 07:58PM  US stocks close mixed as Nasdaq ekes out gains Investing.com
02:03PM  Stock market climbs as health-care shares extend rally MarketWatch
02:03PM  Merck's Powerful Rally Is Coming So Back Up the Truck TheStreet.com
10:12AM  Merck's Keytruda on a Roll: Can it Retain the Momentum? Zacks
08:48AM  Merck and Premier Inc. Expand Collaboration to Address Chronic Care and Vaccination Rates Business Wire
Jun-21-17 04:16PM  S&P closes lower after oil drops more than 2% again CNBC
03:00PM  Amgen An Undervalued Industry Leader Forbes
01:50PM  Dems Roast Trump for Leaving Medicare Out of Drug Price Order TheStreet.com
Jun-20-17 04:15PM  Could Tesaro Overcome Clovis' Lead On Combos With Merck & Co.? Investor's Business Daily
02:25PM  Trump drug pricing order may be weeks away CNBC
08:27AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : June 20, 2017 Capital Cube
07:36AM  Regenerons Praluent May See Gradual Increase in 2017 Demand Market Realist
07:36AM  Key Updates on Eli Lillys Jardiance Market Realist
Jun-19-17 09:42AM  The Amount You Pay for Cancer Drugs May Double -- Here's Why Motley Fool
Jun-16-17 07:37AM  5 best bets in biotech: Expert CNBC Videos
Jun-15-17 10:47AM  Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch Motley Fool
Jun-14-17 11:42AM  Merck & Co., Inc. : MRK-US: Dividend Analysis : June 15th, 2017 (record date) : By the numbers : June 14, 2017 Capital Cube
08:32AM  Dow Jones Industrial Average And Dow Stocks: News And Analysis Investor's Business Daily
Jun-13-17 07:29PM  Dow makes history as tech and financials gain Investing.com
04:09PM  Dow's Merck Pauses Cancer Trials To Investigate Keytruda-Tied Deaths Investor's Business Daily
03:45PM  Industry News And Stocks To Watch Investor's Business Daily
03:41PM  Merck's Keytruda Hit With Safety Snag Motley Fool
11:10AM  Merck Shares Trade Down After 2 Late-Stage Trials Suspended TheStreet.com
09:43AM  Merck Stalls Enrolment in Two Myeloma Studies of Keytruda Zacks
09:30AM  The Zacks Analyst Blog Highlights: Facebook, Wal-Mart, Merck, Kellogg and PACCAR Zacks
08:03AM  3 Stocks to Watch on Tuesday: Shopify Inc (US) (SHOP), Under Armour Inc (UAA) and Merck & Co., Inc. (MRK) InvestorPlace
Jun-12-17 05:18PM  Merck to pause two late-stage studies testing Keytruda in myeloma Reuters
04:59PM  Merck to pause two late-stage studies testing Keytruda in myeloma Reuters
04:30PM  Merck shares slip as blood cancer drug study enrollment paused MarketWatch
04:29PM  Merck pauses enrollment in two cancer studies CNBC Videos
04:24PM  Merck Pauses Enrolling Blood Cancer Studies, Cites Deaths Bloomberg
04:15PM  Merck Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTRUDA® (pembrolizumab) in Combination with Other Therapies Business Wire
08:55AM  Short Sellers Grow More Selective on Major Pharma 24/7 Wall St.
08:43AM  Merck's Diabetes Drug Meets Primary Endpoint in Key Studies Zacks
Jun-10-17 01:00PM  Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies Business Wire
Jun-09-17 08:46AM  Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises Zacks
05:00AM  Cancer Setback Leaves Bristol-Myers Vulnerable to Takeover Bloomberg
Jun-08-17 02:41PM  The Best Hep C Drug Stock to Buy in 2017 Motley Fool
02:28PM  Why Is NewLink Genetics Losing One-Third of Its Value Today? Motley Fool
09:21AM  Organovo Holdings Still Not Back on Track Motley Fool
Jun-07-17 12:56PM  ASCO Was A Bust For Biotech Barrons.com
Jun-06-17 05:54PM  Merck's Cancer Drug Keytruda Positive in Clinical Studies Zacks
05:41PM  An Unprecedented FDA Approval Bodes Well for this Drug Stock Motley Fool
08:15AM  Corporate News Blog - Incyte and Merck Release Phase-1/2 Clinical Trial Data for Epacadostat in Combination with KEYTRUDA(R) for Treatment of NSCLC Accesswire
Jun-05-17 01:59PM  Bristol-Myers Squibb: Value Or Value Trap? Barrons.com
01:33PM  Here's Why Loxo Oncology Soared as Much as 58.5% Today Motley Fool
12:17PM  Why Dynavax Technologies Corporation Stock Soared Today Motley Fool
11:29AM  Incyte Announces Data on Enzyme Inhibitor with Keytruda Zacks
11:03AM  Top Ranked Income Stocks to Buy for June 5th Zacks
09:30AM  The Zacks Analyst Blog Highlights: General Electric, Walt Disney, Merck, Pfizer and Chevron Zacks
09:16AM  Merck's Grip on a Hot Cancer-Drug Market May Tighten Bloomberg
07:30AM  Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Mercks KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 Business Wire
07:05AM  New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Mercks KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer Business Wire
07:00AM  Updated Data from ECHO-202 Trial of Incytes Epacadostat in Combination with Mercks KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types Business Wire
03:26AM  Merck (MRK) Up 2.3% Since Earnings Report: Can It Continue? Zacks
Jun-04-17 10:00AM  New Monotherapy Data for Mercks KEYTRUDA® (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting Business Wire
09:00AM  With More than One-Year Follow-Up, Mercks KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure Business Wire
Jun-03-17 09:00AM  Combination of Incytes Epacadostat plus Mercks KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Business Wire
08:30AM  New Data Show Durability of Response for Mercks KEYTRUDA® (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type Business Wire
08:00AM  Longer Term Follow-Up Data with Mercks KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting Business Wire
07:30AM  Loxo's targeted drug helps variety of advanced cancers in small study Reuters
Jun-02-17 04:18PM  Dow 30 Stock Roundup: GE Inks Deals Worth $5.58B in Vietnam, Merck Buys Rights to Alzheimer Antibody Zacks
04:10PM  Bristol Drug Shows Promise In Treatment Of Cervical Cancer Investor's Business Daily
12:49PM  Stocks to watch during ASCO CNBC Videos
10:49AM  Aduro's Drug Gets Clearance by the FDA for Solid Tumors Zacks
08:12AM  Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More Zacks
07:49AM  Merck reports positive results for late-stage trial comparing its Keytruda against Bristol-Myers' Yervoy MarketWatch
07:30AM  With Nearly Three Years of Follow-Up, KEYTRUDA® (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma Business Wire
06:56AM  Cancer drug prices could double or triple thanks to this popular but unproven drug trend MarketWatch
Jun-01-17 08:00AM  Merck to Present at the Bernsteins 33rd Annual Strategic Decisions Conference Business Wire
May-31-17 04:05PM  Big Pharma Diabetes Drugs Not So Sweet. What's in Store? Zacks
11:46AM  Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose Zacks
May-30-17 07:01PM  Britain backs first-line use of Merck's Keytruda under cancer fund Reuters
01:44PM  Analysts Recommendations for Merck in May 2017 Market Realist
08:58AM  Tracking The Busy June PDUFA Calendar Benzinga
08:00AM  Merck Highlights Ongoing Commitment to Fighting Infectious Diseases With More than 20 Data Presentations at ASM Microbe 2017 Business Wire
07:00AM  Merck Receives FDA Approval of ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients Business Wire
May-27-17 08:40AM  Top Presentations to Look for at ASCO 24/7 Wall St.
May-26-17 12:44PM  Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others Zacks
12:10PM  Cambridge biotech Enumeral faces uncertain future as cash dries up American City Business Journals
10:20AM  UnitedHealth's (UNH) Business Unit Collaborates with Merck Zacks
09:42AM  Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer Zacks
09:30AM  The Zacks Analyst Blog Highlights: Merck, 3M, United Technologies, Ford Motor and Humana Zacks
07:47AM  Here's How the FDA Just Helped Trump Deliver on a Big Promise Motley Fool
07:37AM  Changes in Sanofis Valuation after Its 1Q17 Earnings Market Realist
May-25-17 02:28PM  New Stock Research Reports for Merck, 3M and United Technologies Zacks
02:00PM  Optum and Merck Collaborate to Advance Value-Based Contracting of Pharmaceuticals Business Wire
09:45AM  Major Pharma Short Interest Surges 24/7 Wall St.
09:24AM  Radius Health Osteoporosis Drug Positive in Phase III Study Zacks
09:06AM  Performance of Mercks Animal Health Segment in 1Q17 Market Realist
08:15AM  Blog Coverage Merck's KEYTRUDA Becomes First Cancer Drug to be Approved by FDA Based on a Common Biomarker Instead of the Location of the Tumor Accesswire
08:00AM  Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau Business Wire
07:35AM  Mercks Immunology and Cardiovascular Franchise in 1Q17 Market Realist
May-24-17 10:36AM  Performance of Mercks Diabetes Portfolio in 1Q17 Market Realist
10:28AM  AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk Zacks
10:18AM  Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers Zacks
09:06AM  Gardasil and Mercks Vaccines Business in 1Q17 Market Realist
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has clinical collaboration agreement with Aduro Biotech, Inc. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIDDER C ROBERTDirectorMay 12Option Exercise35.195,000175,95014,317May 12 04:58 PM
KIDDER C ROBERTDirectorMay 12Sale63.545,000317,6959,317May 12 04:58 PM
Davis Robert MEVP, Global Svcs & CFOMay 09Option Exercise0.0085,8810118,031May 09 04:42 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 09Option Exercise0.002,576023,668May 09 04:42 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 09Option Exercise0.002,576017,068May 09 04:42 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 02Option Exercise0.003,092043,637May 03 09:54 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,092046,416May 03 09:52 AM
Schechter Adam HEVP & Pres-Global Human HealthApr 03Sale63.4853,8503,418,166116,336Apr 04 06:36 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM